Personalized Antisense Oligonucleotide Therapy for A Single Participant With TARDBP ALS

Completed · Phase 1/Phase 2

Conditions studied: Amyotrophic Lateral Sclerosis

In brief

This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in TARDBP.

Key facts

Study ID

NCT07095712

Run by

n-Lorem Foundation

People needed

1

Starts

2024-11-25

Expected to finish

2025-12-16

Last updated by the study team

2026-04-09

Who can join

Age: 49 and older, up to 49. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Informed consent/assent provided by the participant (when appropriate), and/or participant's parent(s) or legally authorized representative(s)
• Ability to travel to the study site and adhere to study-related follow-up examinations and/or procedures and provide access to participant's medical records
• Genetically confirmed neurological disorder

You may not qualify if…

• Participant has any condition that in the opinion of the Site Investigator would ultimately prevent the completion of study procedures
• Use of an investigational medication within less than 5 half-lives of the drug at enrollment

Where it is running

• Columbia University, Irving Medical Center — New York, New York, United States
• Houston Methodist — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.